A synthetic peptide derived from a protein found in human gastric juice. Known for its remarkable tissue healing properties across multiple body systems. FDA classified as Category 2 in 2023, restricting compounding.

Is BPC-157 FDA approved?

No, BPC-157 is not FDA approved. Current status: Preclinical - FDA Category 2 (restricted from compounding)

What are the side effects of BPC-157?

Reported side effects of BPC-157 include: Generally well-tolerated in preclinical studies, Nausea, Dizziness, Injection site reactions, Fatigue, Headache, May trigger histamine release - use caution with MCAS or histamine sensitivity, Potential concern for tumor promotion (angiogenesis), Limited long-term human safety data.

What is the typical dosing for BPC-157?

Doses observed in research studies. Common doses observed in research: 250-500 mcg twice daily, 200-300 mcg/kg in animal studies. Duration: 4-12 weeks in most research protocols. Administration: Subcutaneous injection near injury site, or systemic.

Healing

BPC-157

Also known as: Body Protection Compound-157, Pentadecapeptide BPC 157

Preclinical

Popular For

Injury recovery, gut healing, joint and tendon repair

Key Facts: BPC-157

Category: Healing
FDA Status: Not FDA Approved
Clinical Status: Preclinical - FDA Category 2 (restricted from compounding)
Administration: Subcutaneous injection near injury site, or systemic
Typical Dose: 250-500 mcg twice daily
Frequency: 1-2x daily
Evidence Level: Animal Studies
Duration: 4-12 weeks in most research protocols

Also Known As

Body Protection Compound-157, Pentadecapeptide BPC 157

Mechanism of Action

BPC-157 modulates the nitric oxide system, promotes angiogenesis (new blood vessel formation), and upregulates growth hormone receptors. It also interacts with the dopaminergic system and has been shown to accelerate tendon-to-bone healing by promoting collagen synthesis.

Research Summary

Extensive preclinical studies demonstrate efficacy in healing tendons, ligaments, muscles, and the GI tract. 2025 AJSM systematic review: Of 544 articles screened, only 1 clinical study met inclusion criteria (rest were animal studies). Only 3 small human pilot studies exist (fewer than 30 total subjects). No pharmaceutical company has initiated FDA trials due to lack of patentability. FDA placed BPC-157 in Category 2 in September 2023.

Clinical Status:Preclinical - FDA Category 2 (restricted from compounding)

Trial Progress:Preclinical

Pre

III

FDA

Dosing Information

Animal Studies·Primarily animal/preclinical research

Note: Animal study doses may not translate directly to humans.

Typical DosingⓘDoses commonly used by people in practice, based on community reports and anecdotal experience.

Community experience

Common Dose

250-500 mcg twice daily

Range

200-1,000 mcg per day total

Frequency

1-2x daily

Often injected subcutaneously near injury site for localized healing. Systemic administration also common. Many users split into morning and evening doses.

Research DosingⓘDoses from published scientific studies and clinical trials. May include human or animal research.

Scientific studies

Doses observed in research studies

Doses from Studies

250-500 mcg twice daily

Preclinical Research - Doses from animal/in-vitro studies ↗

200-300 mcg/kg in animal studies

Preclinical Research - Doses from animal/in-vitro studies ↗

Duration

4-12 weeks in most research protocols

Administration

Subcutaneous injection near injury site, or systemic

Timing & Administration

Best Time to Take

Morning and evening (or near injury site timing)

1-2 times daily, consistent timing

Food Recommendation

With or without food

Why This Timing?

BPC-157 has systemic healing effects. Split dosing maintains stable levels. Can be timed around activity for injury healing.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

●Generally well-tolerated in preclinical studies
●Nausea
●Dizziness
●Injection site reactions
●Fatigue
●Headache
●May trigger histamine release - use caution with MCAS or histamine sensitivity
●Potential concern for tumor promotion (angiogenesis)
●Limited long-term human safety data

References

Related Peptides

Peptides commonly compared with BPC-157 or used in similar applications.

TB-500

Preclinical

A synthetic 17-amino acid fragment of Thymosin Beta-4 (TB-4). Unlike TB-4, TB-500 has a longer half-life (~2-4 days vs ~2 hours) and is the active region responsible for tissue repair and cell migration. Note: Many vendors mislabel TB-4 as 'TB-500' in premixed products.

Healing

GHK-Cu

Clinical Trials

A naturally occurring copper-binding peptide found in human plasma, saliva, and urine. Widely used in skincare for its wound healing and anti-aging properties.

Skin & Hair

Pentadecapeptide

Preclinical

The full 15-amino acid sequence that includes BPC-157. While BPC-157 is more commonly discussed, the full pentadecapeptide has similar healing properties derived from gastric juice.

Healing

Thymosin Beta-4

Clinical Trials

The full 43-amino acid protein that TB-500 is derived from. Naturally occurring in most human tissues, TB-4 has a shorter half-life (~2 hours) compared to its synthetic fragment TB-500 (~2-4 days). Often mislabeled as 'TB-500' by vendors in premixed products.

Healing

Ziconotide

FDA

A synthetic cone snail venom peptide for severe chronic pain. The first intrathecal non-opioid analgesic FDA approved.

Healing

Wolverine Stack

Preclinical

The most popular healing peptide combination, combining BPC-157 (10mg) and TB-500 (10mg). Named after the Marvel character's regenerative abilities. Used for accelerated injury recovery, joint support, and tissue repair.

Peptide Blend

How to Use BPC-157 BPC-157 Alternatives Compare with Similar Browse All Peptides

Looking for a trusted vendor?

Pro members get access to verified vendors with quality standards & exclusive discount codes.

View Verified Vendors

PRO

Want updates on BPC-157 research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Back to all peptides